Labcorp Holdings Inc. (NYSE:LH) Stock Has Consensus Target Price of $337.73 According to Analysts

Labcorp Holdings Inc. (NYSE:LH) has been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $347.92.

LH has been the subject of a number of research analyst reports. Piper Sandler increased their target price on Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Barclays set a $380.00 price target on Labcorp in a report on Wednesday. Weiss Ratings raised Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday, October 21st. Leerink Partners set a $410.00 price objective on Labcorp in a research note on Wednesday. Finally, Robert W. Baird set a $352.00 price objective on Labcorp in a research note on Friday, July 31st.

Labcorp Stock Up 8.8%

LH stock opened at $360.21 on Monday. Labcorp has a 52-week low of $244.52 and a 52-week high of $371.00. The company’s 50 day simple moving average is $321.91 and its 200-day simple moving average is $286.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.80 and a quick ratio of 1.53. The firm has a market capitalization of $29.21 billion, a P/E ratio of 29.79, a P/E/G ratio of 1.88 and a beta of 0.87.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Wednesday, October 28th. The medical research company reported $4.78 EPS for the quarter, beating the consensus estimate of $4.64 by $0.14. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm earned $4.18 EPS. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts anticipate that Labcorp will post 18.32 EPS for the current year.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Tuesday, November 24th. Labcorp’s dividend payout ratio (DPR) is currently 23.82%.

Insider Activity at Labcorp

In other news, CEO Adam H. Schechter sold 4,669 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total value of $1,495,807.53. Following the transaction, the chief executive officer directly owned 102,565 shares of the company’s stock, valued at approximately $32,858,749.05. This represents a 4.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy B. Summy sold 924 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total transaction of $283,427.76. Following the completion of the transaction, the executive vice president directly owned 6,956 shares in the company, valued at $2,133,683.44. This trade represents a 11.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 8,593 shares of company stock valued at $2,733,295. Corporate insiders own 0.84% of the company’s stock.

Institutional Trading of Labcorp

Institutional investors have recently bought and sold shares of the company. Moss Adams Wealth Advisors LLC raised its stake in Labcorp by 6.1% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 1,460 shares of the medical research company’s stock valued at $450,000 after acquiring an additional 84 shares during the period. Modera Wealth Management LLC lifted its holdings in Labcorp by 3.5% during the 3rd quarter. Modera Wealth Management LLC now owns 1,433 shares of the medical research company’s stock valued at $442,000 after purchasing an additional 49 shares during the last quarter. Everett Harris & Co. CA lifted its holdings in Labcorp by 3.9% during the 3rd quarter. Everett Harris & Co. CA now owns 129,602 shares of the medical research company’s stock valued at $39,932,000 after purchasing an additional 4,913 shares during the last quarter. D.A. Davidson & CO. boosted its position in Labcorp by 3.0% during the third quarter. D.A. Davidson & CO. now owns 21,540 shares of the medical research company’s stock worth $6,637,000 after purchasing an additional 619 shares during the period. Finally, William Mack & Associates Inc. bought a new position in Labcorp during the third quarter worth $42,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Key Labcorp News

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Quarterly results exceeded expectations. Labcorp reported adjusted EPS of $4.78, above the $4.64–$4.65 analyst consensus, while revenue reached $3.81 billion versus expectations of approximately $3.76 billion. EPS increased from $4.18 a year earlier and revenue grew 6.9%. Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 enterprise revenue-growth outlook to 5.9%–6.7% and adjusted EPS guidance to $18.30–$18.70, reinforcing expectations for continued operating momentum. Labcorp Boosts FY26 Outlook
• Positive Sentiment: Growth was broad-based. Diagnostics Laboratories revenue rose 6.5% to $2.95 billion, while Biopharma Laboratory Services revenue increased 8.5% to $866.7 million. Expanding margins and strong revenue growth were also highlighted as key quarterly positives. LH Stock Rises on Q3 Earnings and Revenue Beat
• Positive Sentiment: Expansion and innovation may support future growth. Labcorp announced or completed four transactions, including the acquisition of MLM Medical Labs and agreements involving BioReference Health, Myriad Genetics and Millennium Health. The FDA also approved its PGDx elio tissue complete companion diagnostic for advanced melanoma. Separately, Labcorp and Waters are expanding access to FDA-approved HPV screening tests by late 2026.
• Neutral Sentiment: Capital deployment remains active. Labcorp invested $255.5 million in acquisitions and paid $58.2 million in dividends during the quarter, signaling continued investment but also meaningful cash commitments.
• Negative Sentiment: Insider selling is a potential overhang. Reported insider activity showed nine sales and no purchases over the past six months, including sales by CEO Adam Schechter. This does not offset the strong operating results but may concern some investors after the stock’s recent advance.

Labcorp Company Profile

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.